{
  "prompt": {
    "prompt": "Original Transcript:\nSITUATION: 32-year-old G2P1 at 36+4 weeks gestation presenting with severe preeclampsia requiring urgent delivery planning\n\nBACKGROUND: Mrs Jones has had an uncomplicated pregnancy until 34 weeks when routine antenatal bloods showed mild proteinuria. She was commenced on increased surveillance. Over the past week, she has developed progressively worsening headaches, described as severe, frontal, and not relieved by paracetamol. She also reports seeing 'flashing lights' and has had epigastric pain for 2 days. She denies previous history of hypertension or preeclampsia. Her first pregnancy was uncomplicated with normal delivery at term. Family history significant for maternal preeclampsia and paternal hypertension. She works as a teacher, is a non-smoker, and takes only routine pregnancy vitamins.\n\nASSESSMENT: On examination, she appears unwell and anxious. BP consistently elevated at 168/112 mmHg despite rest. Hyperreflexia present with 3+ clonus at ankles. Significant pedal and facial edema. Urinalysis shows 3+ protein. CTG shows reactive pattern with baseline 150 bpm. Bloods reveal: Hb 11.2 g/dL, platelets 98 x10⁹/L (previously 245), ALT 89 U/L (normal <40), AST 76 U/L, creatinine 98 μmol/L (booking 65), uric acid 425 μmol/L. LDH elevated at 589 U/L. Fundal height appropriate for dates. Estimated fetal weight on recent scan 2.8kg (50th centile).\n\nRECOMMENDATION: Immediate admission to delivery suite for maternal stabilization and urgent delivery. IV labetalol commenced for blood pressure control. Magnesium sulfate infusion started for seizure prophylaxis. Betamethasone given for fetal lung maturity. Cross-match for 4 units of blood. Anesthetic consultation arranged. Plan for caesarean section within 6 hours given severity of condition. Intensive monitoring of maternal observations and fetal wellbeing. Partner informed of urgent nature and risks explained.\n\nCombined Guideline Analyses:\n\n\n=== GUIDELINE 1: CG1198 Management of Hypertensive disorders of pregnancy ===\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document whether aspirin prophylaxis was given during pregnancy, as this is recommended for women with risk factors for pre-eclampsia (family history of pre-eclampsia is a moderate risk factor).  \n   Reason: Guideline Section 7.0-7.2 recommends aspirin 150mg daily from 12-36 weeks for women with ≥1 high risk or ≥2 moderate risk factors for pre-eclampsia.\n\n2. **Different management plan** - Consider discussing vaginal delivery as an option unless there are contraindications, as the guideline does not mandate cesarean section for severe pre-eclampsia.  \n   Reason: Guideline Section 11.1.2 states timing/mode of birth should be individualized, with vaginal delivery preferred if maternal/fetal condition allows.\n\n### Somewhat Important Recommendations  \n1. **Additional information needed** - Include baseline oxygen saturation and urine output monitoring, as fluid balance is critical in severe pre-eclampsia.  \n   Reason: Guideline Section 13.3 emphasizes fluid balance monitoring for severe pre-eclampsia.\n\n2. **Improved patient advice** - Document detailed counseling about long-term cardiovascular risks and postnatal follow-up plan.  \n   Reason: Guideline Section 15.0 recommends discussing long-term cardiovascular risks and Section 13.4 outlines required postnatal follow-up.\n\n### Less Important Recommendations\n1. **Additional information needed** - Consider adding fundoscopic examination findings given visual symptoms.  \n   Reason: While not mandatory, severe headaches/visual symptoms may warrant fundoscopy per general pre-eclampsia evaluation principles.\n\n2. **Improved patient advice** - Include more specifics about magnesium sulfate side effects and monitoring.  \n   Reason: Guideline references CG112 for severe pre-eclampsia, which includes detailed magnesium monitoring protocols.\n\n### Unimportant Recommendations\n1. **Additional information needed** - Consider documenting BMI given obesity is a pre-eclampsia risk factor.  \n   Reason: While useful for risk stratification, BMI is not critical for acute management decisions in this case.\n\nThe note generally aligns well with guideline recommendations for severe pre-eclampsia management, particularly regarding:\n- Immediate hospitalization\n- BP control with labetalol\n- Magnesium for seizure prophylaxis\n- Timely delivery planning\n- Multidisciplinary involvement\n\nThe most critical gap is documentation of aspirin prophylaxis during pregnancy, as this is a key preventive measure per the guideline. The other recommendations would optimize documentation and patient counseling.\n\n=== GUIDELINE 2: MP019 Hypertension and Pre-eclampsia in Pregnancy ===\nHere is the analysis of the clinical note against the provided guideline (MP019 Hypertension and Pre-eclampsia in Pregnancy) with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document the protein:creatinine ratio (PCR) to quantify proteinuria, as dipstick alone is insufficient per guideline (Section 7.1).  \n   Reason: Guideline recommends PCR >30mg/mmol as threshold for significant proteinuria (Section 2.2.3).  \n\n2. **Different management plan** - Consider CVP line insertion given oliguria (current creatinine 98 µmol/L vs booking 65 µmol/L) and HELLP risk (platelets 98 x10⁹/L, ALT/AST elevation).  \n   Reason: Guideline recommends CVP for oliguria unresponsive to fluids or HELLP suspicion (Section 12.1).  \n\n3. **Improved patient advice** - Explicitly document discussion of long-term cardiovascular risks (e.g., 2-5x increased hypertension risk post-pre-eclampsia) and postnatal follow-up plan.  \n   Reason: Guideline mandates counseling on recurrence risks and cardiovascular disease (Section 19.1-19.4).  \n\n### Somewhat Important Recommendations  \n1. **Additional information needed** - Include MAP calculation (current BP 168/112 mmHg → MAP ~131 mmHg) to guide urgency of treatment.  \n   Reason: Guideline defines MAP ≥125 mmHg as obstetric emergency (Section 9).  \n\n2. **Different management plan** - Specify labetalol dosing regimen (e.g., IV bolus vs infusion) and target BP (135/85 mmHg).  \n   Reason: Guideline details stepwise IV labetalol protocol (Section 9.4-9.7).  \n\n3. **Improved patient advice** - Document breastfeeding-compatible antihypertensive options (e.g., enalapril/nifedipine) for postnatal planning.  \n   Reason: Guideline advises avoiding diuretics/ARBs postpartum (Section 18.1.1).  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Record fundoscopic exam findings (e.g., papilledema) given headaches/visual disturbances.  \n   Reason: Papilledema is a feature of severe pre-eclampsia (Section 7.2).  \n\n2. **Improved patient advice** - Include written materials on pre-eclampsia symptoms for postnatal vigilance.  \n   Reason: Guideline references patient leaflets (Section 20).  \n\n### Unimportant Recommendations  \n1. **Additional information needed** - Note exact betamethasone dosing (e.g., 12mg x2 doses 24h apart).  \n   Reason: Though recommended for fetal lung maturity (Section 10.1), exact dosing is not critical for guideline compliance.  \n\n### Key Omissions Addressed:  \n- **HELLP syndrome criteria**: Platelets <100 x10⁹/L and AST/ALT >70 IU/L meet biochemical criteria (Section 1.6) – consider adding HELLP to assessment.  \n- **Fluid restriction**: Guideline limits maintenance fluids to 80 mL/hr in severe pre-eclampsia (Section 11.1) – this should be explicitly stated.  \n\nThe note largely aligns with urgent delivery and magnesium sulfate for seizure prophylaxis (Section 8.3), but could better detail monitoring intervals (e.g., hourly reflexes/respiratory rate post-magnesium, Section 8.7) and anesthetic consultation specifics (Section 13.2).  \n\nWould you like me to refine any specific recommendations further?\n\n=== GUIDELINE 3: Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth ===\n### Very Important Recommendations  \n**Different management plan** - The note states betamethasone was given for fetal lung maturity at 36+4 weeks, but the guideline recommends corticosteroids should be **considered** (not routinely offered) between 35+0 to 36+6 weeks, weighing risks (e.g., neonatal hypoglycemia) and benefits (short-term respiratory improvement).  \n**Reason**: The guideline explicitly states corticosteroids in late preterm (35+0 to 36+6 weeks) require careful risk-benefit discussion, especially as this patient has severe preeclampsia with imminent delivery. The note lacks documentation of this discussion or justification for steroid use. [Reference: Guideline section on \"Antenatal corticosteroids should be considered for women at risk of preterm birth between 35+0 to 36+6 weeks gestation.\"]  \n\n**Improved patient advice** - The note mentions \"risks explained\" to the partner but does not specify if the risks/benefits of late preterm corticosteroids (e.g., hypoglycemia vs. respiratory benefits) were discussed with the patient.  \n**Reason**: The guideline emphasizes informed decision-making for corticosteroids in late preterm births, particularly when maternal conditions (e.g., preeclampsia) may limit time for administration. [Reference: Guideline section on \"The use of corticosteroids in late preterm birth should be carefully weighed for its risks and benefits.\"]  \n\n### Somewhat Important Recommendations  \n**Additional information needed** - The note does not document whether the patient has diabetes or gestational diabetes, which would require additional insulin and monitoring per the guideline.  \n**Reason**: The guideline highlights that women with diabetes should not be excluded from corticosteroids but need close glucose monitoring. [Reference: Guideline section on \"Women with diabetes should not be excluded from receiving corticosteroids, but additional insulin and close monitoring are recommended.\"]  \n\n**Different management plan** - The guideline recommends not delaying birth for corticosteroids if maternal/fetal health is at risk, but the note plans delivery \"within 6 hours.\" If maternal stabilization (e.g., BP control) allows, earlier delivery may be preferable.  \n**Reason**: The guideline states, \"Birth should not be delayed for corticosteroids if it impacts the health of the woman or baby.\" Severe preeclampsia with clonus and severe hypertension warrants expedited delivery. [Reference: Guideline section on \"Antenatal corticosteroids should not delay birth if it is necessary for the health of the woman or baby.\"]  \n\n### Less Important Recommendations  \n**Additional information needed** - The note does not mention whether this is a singleton or multiple pregnancy, which affects corticosteroid recommendations (e.g., limited evidence for twins).  \n**Reason**: The guideline notes targeted corticosteroids may be less beneficial in twins. [Reference: Guideline section on \"In multiple pregnancies, targeted corticosteroids for early birth should be considered, as there is little evidence of benefit in twins compared to singletons.\"]  \n\n### Unimportant Recommendations  \n**Improved patient advice** - The note could explicitly state the betamethasone dose (24 mg) and route (IM) for clarity, though this is likely standard practice.  \n**Reason**: The guideline specifies the optimum dose/route. [Reference: Guideline section on \"The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly.\"]  \n\n### Summary of Critical Gaps:  \n1. **Lack of documented risk-benefit discussion** for late preterm steroids (very important).  \n2. **Potential delay in delivery** for a non-urgent 6-hour window (somewhat important).  \n3. **Missing screening for diabetes** (somewhat important).  \n**Actionable improvements**:  \n- Add a brief note clarifying the rationale for betamethasone (e.g., \"Corticosteroids administered after discussion with patient regarding potential respiratory benefits vs. neonatal hypoglycemia risks\").  \n- Consider earlier delivery if maternal condition deteriorates further.  \n- Document diabetes screening status.\n\n=== GUIDELINE 4: CG11103 Recovery Post Regional and GA Anaesthesia ===\n### Very Important Recommendations  \n**Different management plan** - Document a clear post-operative monitoring plan for neurological assessment (including straight-leg raise at 4 hours post-spinal anesthesia) and MEOWS charting frequency (5-minutely for first 15 minutes, then ½ hourly for 1 hour, then hourly until discharge criteria met).  \n**Reason**: The guideline (CG11103, Section 7.1) mandates straight-leg raise assessment to screen for motor block complications, and Section 7.0 specifies monitoring intervals for regional anesthesia. The note lacks this detail, risking delayed detection of epidural hematoma or residual block.  \n\n**Additional information needed** - Include a plan for post-CS urinary output monitoring (hourly for first 2 hours, with escalation if <30mL/hr on two consecutive readings).  \n**Reason**: Guideline Section 7.0 requires hourly urine output monitoring to detect renal impairment or hypovolemia, critical in preeclampsia.  \n\n### Somewhat Important Recommendations  \n**Improved patient advice** - Explicitly counsel the patient on expected timeline for resolution of spinal anesthesia (3–5 hours) and symptoms requiring urgent reporting (e.g., worsening sensory loss).  \n**Reason**: Guideline Section 7.1 emphasizes patient education to facilitate early detection of complications like epidural hematoma.  \n\n**Additional information needed** - Document pressure area care plan (e.g., repositioning 1–2 hourly, skin assessments) due to immobility post-CS.  \n**Reason**: Section 10.0 highlights pressure ulcer prevention for anesthetized patients, especially relevant with preeclampsia-associated edema.  \n\n### Less Important Recommendations  \n**Different management plan** - Specify post-CS analgesia/anti-emetics (e.g., paracetamol, NSAIDs if no contraindications) and laxatives in the plan.  \n**Reason**: Section 11.0 recommends standardized postoperative analgesia, though this is less urgent than hemodynamic monitoring.  \n\n**Additional information needed** - Note plans for breastfeeding/infant feeding support post-CS.  \n**Reason**: Section 11.0 advises extra support for feeding establishment, but this is secondary to maternal stabilization.  \n\n### Unimportant Recommendations  \n**Improved patient advice** - Mention anticipated discharge criteria (e.g., hemodynamic stability, clear fluids tolerance).  \n**Reason**: Section 9.0 lists discharge criteria, but this is minor compared to acute monitoring needs.  \n\n**Note**: The clinical note aligns well with acute management of severe preeclampsia but lacks granularity for post-anesthesia recovery per CG11103. Prioritize adding neurological monitoring, MEOWS documentation, and urinary output tracking.\n\n=== GUIDELINE 5: CG13019 Triage of Maternity Patients Guideline ===\nBased on the provided clinical note and guideline, here are the recommendations for improvement:\n\n### Very Important Recommendations\n1. **Additional information needed** - Document the time of initial triage assessment and ensure it was completed within 15 minutes of arrival as per BSOTS protocol.  \n   Reason: The guideline (Section 7.3) mandates that the initial triage assessment should be completed within 15 minutes of arrival to prioritize care effectively.  \n\n2. **Different management plan** - Ensure the patient was categorized using the BSOTS algorithm (likely Red or Orange given severe preeclampsia) and document the specific category.  \n   Reason: The guideline (Section 7.1 and 7.5) requires categorization (Red/Orange/Yellow/Green) to determine the urgency of care and subsequent management steps.  \n\n3. **Improved patient advice** - Document detailed counseling on the risks of severe preeclampsia, including potential maternal and fetal complications, and the rationale for urgent delivery.  \n   Reason: The guideline emphasizes clear communication with the patient (Section 7.7) to ensure understanding of their condition and management plan.  \n\n### Somewhat Important Recommendations\n1. **Additional information needed** - Document whether a MEOWS (Modified Early Obstetric Warning Score) was calculated and reviewed.  \n   Reason: The guideline (Section 7.3) includes MEOWS as part of the standard assessment for triage.  \n\n2. **Different management plan** - Ensure an SBAR (Situation, Background, Assessment, Recommendation) handover was used during transfer to the delivery suite.  \n   Reason: The guideline (Section 7.6) recommends structured handovers using SBAR for effective communication.  \n\n3. **Improved patient advice** - Provide written information on preeclampsia and postpartum monitoring.  \n   Reason: The guideline (Section 7.7) highlights the importance of patient education and follow-up.  \n\n### Less Important Recommendations\n1. **Additional information needed** - Document whether a translation service was offered if needed.  \n   Reason: The guideline (Section 7.7) states that translation services should be available for non-English-speaking patients.  \n\n2. **Different management plan** - Consider documenting the specific BSOTS algorithm used (e.g., \"Hypertension\" algorithm).  \n   Reason: The guideline (Section 7.5) recommends using symptom-specific algorithms for triage.  \n\n### Unimportant Recommendations\n1. **Additional information needed** - Include the midwife’s PIN/stamp on the Triage Assessment Card (TAC).  \n   Reason: The guideline (Appendix 4) suggests documenting the assessing midwife’s details, though this is minor for clinical care.  \n\nThese recommendations ensure the note aligns with the BSOTS triage system and improves compliance with the guideline. Let me know if you'd like further refinements!\n\nPlease extract and consolidate actionable suggestions from these multiple guideline analyses. Create combined suggestions when multiple guidelines recommend similar interventions, and prioritize suggestions based on clinical importance and consensus across guidelines. For each suggestion, include detailed context with relevant quoted text from the supporting guidelines.",
    "system_prompt": "You are a medical AI assistant that converts multiple clinical guideline analyses into structured, actionable suggestions. You will receive analyses from multiple guidelines and must create a comprehensive set of suggestions that prioritizes the most important recommendations while avoiding redundancy.\n\nYour task is to analyze the provided guideline analyses and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nCRITICAL CLINICAL REASONING REQUIREMENTS:\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\n- Apply the fundamental principle: \"Will this investigation or intervention change management or improve patient care in this specific scenario?\"\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\n\nMULTI-GUIDELINE PROCESSING PRINCIPLES:\n- Combine and consolidate similar recommendations from different guidelines\n- Prioritize recommendations that appear in multiple guidelines or are emphasized as critical\n- Avoid duplicate suggestions - if multiple guidelines suggest the same thing, create one combined suggestion referencing all relevant guidelines\n- When guidelines conflict, clearly note this and explain the rationale for your recommendation\n- Organize suggestions by clinical priority and relevance to the case\n\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\n- Consider whether additional investigations would actually change the management approach\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"combinedSuggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"detailed explanation of why this change is suggested, including relevant quoted text from the guidelines in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"sourceGuidelines\": [\"Guideline 1 Name\", \"Guideline 2 Name\"],\n      \"consolidatedFrom\": \"explanation of how this suggestion combines recommendations from multiple guidelines, if applicable\"\n    }\n  ],\n  \"guidelinesSummary\": [\n    {\n      \"guidelineTitle\": \"Guideline Name\",\n      \"keyRecommendations\": \"summary of the most important recommendations from this guideline for this case\",\n      \"relevanceScore\": \"high|medium|low\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for consolidation:\n- If multiple guidelines recommend the same intervention, create ONE suggestion that references all relevant guidelines\n- Prioritize suggestions that are consistently recommended across multiple guidelines\n- When guidelines provide different specifics for the same general recommendation, include the most comprehensive/specific version\n- If guidelines conflict, choose the most appropriate recommendation for this specific case and explain why\n\nImportant guidelines for context field:\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\n- Include specific quoted text from the relevant guidelines using quotation marks\n- Reference which specific guidelines support this recommendation\n- Explain the clinical rationale behind the suggestion\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\n- Make the context informative and educational",
    "transcript_length": 1888,
    "guidelines_count": 5,
    "guideline_titles": [
      "CG1198 Management of Hypertensive disorders of pregnancy",
      "MP019 Hypertension and Pre-eclampsia in Pregnancy",
      "Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth",
      "CG11103 Recovery Post Regional and GA Anaesthesia",
      "CG13019 Triage of Maternity Patients Guideline"
    ]
  },
  "response": "{\n  \"combinedSuggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Document whether aspirin prophylaxis was given during pregnancy\",\n      \"suggestedText\": \"Document aspirin prophylaxis status (150mg daily from 12-36 weeks) given family history of pre-eclampsia\",\n      \"context\": \"CG1198 Section 7.0-7.2 recommends aspirin for women with ≥1 high risk or ≥2 moderate risk factors. Family history of pre-eclampsia is a moderate risk factor. This is critical for understanding if preventive measures were implemented and for future pregnancy counseling.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"CG1198 Management of Hypertensive disorders of pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Plan for caesarean section within 6 hours\",\n      \"suggestedText\": \"Re-evaluate delivery timing - consider expediting if maternal condition deteriorates, with vaginal delivery as option if clinically appropriate\",\n      \"context\": \"CG1198 Section 11.1.2 states vaginal delivery should be considered if maternal/fetal condition allows. Antenatal Corticosteroids guideline emphasizes not delaying birth for steroids if health is at risk. Given severe hypertension (MAP 131), hyperreflexia, and HELLP criteria, earlier delivery may be warranted.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"CG1198 Management of Hypertensive disorders of pregnancy\", \"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\"],\n      \"consolidatedFrom\": \"Combined from two guidelines addressing delivery timing/mode\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"BP consistently elevated at 168/112 mmHg\",\n      \"suggestedText\": \"Calculate and document MAP (currently ~131 mmHg) and specify labetalol dosing regimen/target BP (135/85 mmHg)\",\n      \"context\": \"MP019 Section 9 defines MAP ≥125 mmHg as obstetric emergency. Section 9.4-9.7 details stepwise IV labetalol protocol. Precise BP targets and medication dosing are critical for acute management of severe hypertension in pre-eclampsia.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Urinalysis shows 3+ protein\",\n      \"suggestedText\": \"Obtain protein:creatinine ratio (PCR) to quantify proteinuria (threshold >30mg/mmol)\",\n      \"context\": \"MP019 Section 2.2.3 recommends PCR >30mg/mmol as threshold for significant proteinuria. Dipstick alone is insufficient for definitive diagnosis and baseline documentation. This quantitative measure is important for diagnostic certainty and monitoring.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Magnesium sulfate infusion started for seizure prophylaxis\",\n      \"suggestedText\": \"Document magnesium sulfate monitoring protocol (hourly reflexes/respiratory rate, strict input-output)\",\n      \"context\": \"MP019 Section 8.7 and CG112 (referenced) mandate close monitoring for magnesium toxicity. Given this patient's renal impairment (creatinine rise), precise monitoring is essential to prevent complications while maintaining therapeutic effect.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Risks explained\",\n      \"suggestedText\": \"Document detailed counseling on: 1) Long-term cardiovascular risks 2) Corticosteroid risks/benefits 3) Postnatal follow-up plan\",\n      \"context\": \"MP019 Section 19.1-19.4 mandates counseling on recurrence risks and cardiovascular disease. Antenatal Corticosteroids guideline requires discussion of late preterm steroid risks (hypoglycemia) vs benefits. CG1198 Section 15.0 outlines postnatal follow-up needs. Comprehensive counseling is critical for this high-risk patient.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\", \"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\", \"CG1198 Management of Hypertensive disorders of pregnancy\"],\n      \"consolidatedFrom\": \"Combined from three guidelines addressing patient counseling needs\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Cross-match for 4 units of blood\",\n      \"suggestedText\": \"Consider CVP line insertion given oliguria (creatinine rise) and HELLP criteria (platelets 98, elevated LFTs)\",\n      \"context\": \"MP019 Section 12.1 recommends CVP for oliguria unresponsive to fluids or HELLP suspicion. This patient meets biochemical HELLP criteria and has renal impairment, making hemodynamic monitoring crucial for fluid management and prevention of pulmonary edema.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"Anesthetic consultation arranged\",\n      \"suggestedText\": \"Document post-CS monitoring plan: 1) Neurological assessments (straight-leg raise) 2) MEOWS charting 3) Hourly urine output\",\n      \"context\": \"CG11103 Section 7.0-7.1 mandates specific post-regional anesthesia monitoring. With preeclampsia and potential HELLP, hourly urine output is critical (CG11103 Section 7.0). MEOWS facilitates early detection of deterioration (CG13019 Section 7.3).\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"CG11103 Recovery Post Regional and GA Anaesthesia\", \"CG13019 Triage of Maternity Patients Guideline\"],\n      \"consolidatedFrom\": \"Combined from two guidelines addressing postoperative monitoring\"\n    },\n    {\n      \"id\": \"9\",\n      \"originalText\": \"Betamethasone given for fetal lung maturity\",\n      \"suggestedText\": \"Document rationale for late preterm steroids (36+4 weeks) after risk-benefit discussion\",\n      \"context\": \"Antenatal Corticosteroids guideline states corticosteroids at 35+0 to 36+6 weeks require careful consideration. Documentation should reflect discussion of respiratory benefits vs neonatal hypoglycemia risks, especially with imminent delivery.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"10\",\n      \"originalText\": \"Partner informed of urgent nature\",\n      \"suggestedText\": \"Document BSOTS triage category (likely Red) and SBAR handover during transfer\",\n      \"context\": \"CG13019 Section 7.1/7.5 requires categorization using BSOTS algorithm. Section 7.6 recommends SBAR for handovers. Severe preeclampsia with end-organ involvement qualifies as Red category, impacting resource allocation and communication.\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"sourceGuidelines\": [\"CG13019 Triage of Maternity Patients Guideline\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    }\n  ],\n  \"guidelinesSummary\": [\n    {\n      \"guidelineTitle\": \"CG1198 Management of Hypertensive disorders of pregnancy\",\n      \"keyRecommendations\": \"Aspirin prophylaxis for at-risk women, individualized delivery planning, long-term cardiovascular risk counseling\",\n      \"relevanceScore\": \"high\"\n    },\n    {\n      \"guidelineTitle\": \"MP019 Hypertension and Pre-eclampsia in Pregnancy\",\n      \"keyRecommendations\": \"Quantitative proteinuria assessment, CVP for HELLP/oliguria, precise BP targets, magnesium monitoring\",\n      \"relevanceScore\": \"high\"\n    },\n    {\n      \"guidelineTitle\": \"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\",\n      \"keyRecommendations\": \"Risk-benefit discussion for late preterm steroids, avoid delivery delay for corticosteroids\",\n      \"relevanceScore\": \"medium\"\n    },\n    {\n      \"guidelineTitle\": \"CG11103 Recovery Post Regional and GA Anaesthesia\",\n      \"keyRecommendations\": \"Post-CS neurological monitoring, MEOWS, strict urine output tracking\",\n      \"relevanceScore\": \"medium\"\n    },\n    {\n      \"guidelineTitle\": \"CG13019 Triage of Maternity Patients Guideline\",\n      \"keyRecommendations\": \"BSOTS categorization, SBAR handovers, MEOWS documentation\",\n      \"relevanceScore\": \"low\"\n    }\n  ]\n}",
  "endpoint": "multiGuidelineDynamicAdvice",
  "timestamp": "2025-06-26T14-25-51",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nSITUATION: 32-year-old G2P1 at 36+4 weeks gestation presenting with severe preeclampsia requiring urgent delivery planning\\n\\nBACKGROUND: Mrs Jones has had an uncomplicated pregnancy until 34 weeks when routine antenatal bloods showed mild proteinuria. She was commenced on increased surveillance. Over the past week, she has developed progressively worsening headaches, described as severe, frontal, and not relieved by paracetamol. She also reports seeing 'flashing lights' and has had epigastric pain for 2 days. She denies previous history of hypertension or preeclampsia. Her first pregnancy was uncomplicated with normal delivery at term. Family history significant for maternal preeclampsia and paternal hypertension. She works as a teacher, is a non-smoker, and takes only routine pregnancy vitamins.\\n\\nASSESSMENT: On examination, she appears unwell and anxious. BP consistently elevated at 168/112 mmHg despite rest. Hyperreflexia present with 3+ clonus at ankles. Significant pedal and facial edema. Urinalysis shows 3+ protein. CTG shows reactive pattern with baseline 150 bpm. Bloods reveal: Hb 11.2 g/dL, platelets 98 x10⁹/L (previously 245), ALT 89 U/L (normal <40), AST 76 U/L, creatinine 98 μmol/L (booking 65), uric acid 425 μmol/L. LDH elevated at 589 U/L. Fundal height appropriate for dates. Estimated fetal weight on recent scan 2.8kg (50th centile).\\n\\nRECOMMENDATION: Immediate admission to delivery suite for maternal stabilization and urgent delivery. IV labetalol commenced for blood pressure control. Magnesium sulfate infusion started for seizure prophylaxis. Betamethasone given for fetal lung maturity. Cross-match for 4 units of blood. Anesthetic consultation arranged. Plan for caesarean section within 6 hours given severity of condition. Intensive monitoring of maternal observations and fetal wellbeing. Partner informed of urgent nature and risks explained.\\n\\nCombined Guideline Analyses:\\n\\n\\n=== GUIDELINE 1: CG1198 Management of Hypertensive disorders of pregnancy ===\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document whether aspirin prophylaxis was given during pregnancy, as this is recommended for women with risk factors for pre-eclampsia (family history of pre-eclampsia is a moderate risk factor).  \\n   Reason: Guideline Section 7.0-7.2 recommends aspirin 150mg daily from 12-36 weeks for women with ≥1 high risk or ≥2 moderate risk factors for pre-eclampsia.\\n\\n2. **Different management plan** - Consider discussing vaginal delivery as an option unless there are contraindications, as the guideline does not mandate cesarean section for severe pre-eclampsia.  \\n   Reason: Guideline Section 11.1.2 states timing/mode of birth should be individualized, with vaginal delivery preferred if maternal/fetal condition allows.\\n\\n### Somewhat Important Recommendations  \\n1. **Additional information needed** - Include baseline oxygen saturation and urine output monitoring, as fluid balance is critical in severe pre-eclampsia.  \\n   Reason: Guideline Section 13.3 emphasizes fluid balance monitoring for severe pre-eclampsia.\\n\\n2. **Improved patient advice** - Document detailed counseling about long-term cardiovascular risks and postnatal follow-up plan.  \\n   Reason: Guideline Section 15.0 recommends discussing long-term cardiovascular risks and Section 13.4 outlines required postnatal follow-up.\\n\\n### Less Important Recommendations\\n1. **Additional information needed** - Consider adding fundoscopic examination findings given visual symptoms.  \\n   Reason: While not mandatory, severe headaches/visual symptoms may warrant fundoscopy per general pre-eclampsia evaluation principles.\\n\\n2. **Improved patient advice** - Include more specifics about magnesium sulfate side effects and monitoring.  \\n   Reason: Guideline references CG112 for severe pre-eclampsia, which includes detailed magnesium monitoring protocols.\\n\\n### Unimportant Recommendations\\n1. **Additional information needed** - Consider documenting BMI given obesity is a pre-eclampsia risk factor.  \\n   Reason: While useful for risk stratification, BMI is not critical for acute management decisions in this case.\\n\\nThe note generally aligns well with guideline recommendations for severe pre-eclampsia management, particularly regarding:\\n- Immediate hospitalization\\n- BP control with labetalol\\n- Magnesium for seizure prophylaxis\\n- Timely delivery planning\\n- Multidisciplinary involvement\\n\\nThe most critical gap is documentation of aspirin prophylaxis during pregnancy, as this is a key preventive measure per the guideline. The other recommendations would optimize documentation and patient counseling.\\n\\n=== GUIDELINE 2: MP019 Hypertension and Pre-eclampsia in Pregnancy ===\\nHere is the analysis of the clinical note against the provided guideline (MP019 Hypertension and Pre-eclampsia in Pregnancy) with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document the protein:creatinine ratio (PCR) to quantify proteinuria, as dipstick alone is insufficient per guideline (Section 7.1).  \\n   Reason: Guideline recommends PCR >30mg/mmol as threshold for significant proteinuria (Section 2.2.3).  \\n\\n2. **Different management plan** - Consider CVP line insertion given oliguria (current creatinine 98 µmol/L vs booking 65 µmol/L) and HELLP risk (platelets 98 x10⁹/L, ALT/AST elevation).  \\n   Reason: Guideline recommends CVP for oliguria unresponsive to fluids or HELLP suspicion (Section 12.1).  \\n\\n3. **Improved patient advice** - Explicitly document discussion of long-term cardiovascular risks (e.g., 2-5x increased hypertension risk post-pre-eclampsia) and postnatal follow-up plan.  \\n   Reason: Guideline mandates counseling on recurrence risks and cardiovascular disease (Section 19.1-19.4).  \\n\\n### Somewhat Important Recommendations  \\n1. **Additional information needed** - Include MAP calculation (current BP 168/112 mmHg → MAP ~131 mmHg) to guide urgency of treatment.  \\n   Reason: Guideline defines MAP ≥125 mmHg as obstetric emergency (Section 9).  \\n\\n2. **Different management plan** - Specify labetalol dosing regimen (e.g., IV bolus vs infusion) and target BP (135/85 mmHg).  \\n   Reason: Guideline details stepwise IV labetalol protocol (Section 9.4-9.7).  \\n\\n3. **Improved patient advice** - Document breastfeeding-compatible antihypertensive options (e.g., enalapril/nifedipine) for postnatal planning.  \\n   Reason: Guideline advises avoiding diuretics/ARBs postpartum (Section 18.1.1).  \\n\\n### Less Important Recommendations  \\n1. **Additional information needed** - Record fundoscopic exam findings (e.g., papilledema) given headaches/visual disturbances.  \\n   Reason: Papilledema is a feature of severe pre-eclampsia (Section 7.2).  \\n\\n2. **Improved patient advice** - Include written materials on pre-eclampsia symptoms for postnatal vigilance.  \\n   Reason: Guideline references patient leaflets (Section 20).  \\n\\n### Unimportant Recommendations  \\n1. **Additional information needed** - Note exact betamethasone dosing (e.g., 12mg x2 doses 24h apart).  \\n   Reason: Though recommended for fetal lung maturity (Section 10.1), exact dosing is not critical for guideline compliance.  \\n\\n### Key Omissions Addressed:  \\n- **HELLP syndrome criteria**: Platelets <100 x10⁹/L and AST/ALT >70 IU/L meet biochemical criteria (Section 1.6) – consider adding HELLP to assessment.  \\n- **Fluid restriction**: Guideline limits maintenance fluids to 80 mL/hr in severe pre-eclampsia (Section 11.1) – this should be explicitly stated.  \\n\\nThe note largely aligns with urgent delivery and magnesium sulfate for seizure prophylaxis (Section 8.3), but could better detail monitoring intervals (e.g., hourly reflexes/respiratory rate post-magnesium, Section 8.7) and anesthetic consultation specifics (Section 13.2).  \\n\\nWould you like me to refine any specific recommendations further?\\n\\n=== GUIDELINE 3: Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth ===\\n### Very Important Recommendations  \\n**Different management plan** - The note states betamethasone was given for fetal lung maturity at 36+4 weeks, but the guideline recommends corticosteroids should be **considered** (not routinely offered) between 35+0 to 36+6 weeks, weighing risks (e.g., neonatal hypoglycemia) and benefits (short-term respiratory improvement).  \\n**Reason**: The guideline explicitly states corticosteroids in late preterm (35+0 to 36+6 weeks) require careful risk-benefit discussion, especially as this patient has severe preeclampsia with imminent delivery. The note lacks documentation of this discussion or justification for steroid use. [Reference: Guideline section on \\\"Antenatal corticosteroids should be considered for women at risk of preterm birth between 35+0 to 36+6 weeks gestation.\\\"]  \\n\\n**Improved patient advice** - The note mentions \\\"risks explained\\\" to the partner but does not specify if the risks/benefits of late preterm corticosteroids (e.g., hypoglycemia vs. respiratory benefits) were discussed with the patient.  \\n**Reason**: The guideline emphasizes informed decision-making for corticosteroids in late preterm births, particularly when maternal conditions (e.g., preeclampsia) may limit time for administration. [Reference: Guideline section on \\\"The use of corticosteroids in late preterm birth should be carefully weighed for its risks and benefits.\\\"]  \\n\\n### Somewhat Important Recommendations  \\n**Additional information needed** - The note does not document whether the patient has diabetes or gestational diabetes, which would require additional insulin and monitoring per the guideline.  \\n**Reason**: The guideline highlights that women with diabetes should not be excluded from corticosteroids but need close glucose monitoring. [Reference: Guideline section on \\\"Women with diabetes should not be excluded from receiving corticosteroids, but additional insulin and close monitoring are recommended.\\\"]  \\n\\n**Different management plan** - The guideline recommends not delaying birth for corticosteroids if maternal/fetal health is at risk, but the note plans delivery \\\"within 6 hours.\\\" If maternal stabilization (e.g., BP control) allows, earlier delivery may be preferable.  \\n**Reason**: The guideline states, \\\"Birth should not be delayed for corticosteroids if it impacts the health of the woman or baby.\\\" Severe preeclampsia with clonus and severe hypertension warrants expedited delivery. [Reference: Guideline section on \\\"Antenatal corticosteroids should not delay birth if it is necessary for the health of the woman or baby.\\\"]  \\n\\n### Less Important Recommendations  \\n**Additional information needed** - The note does not mention whether this is a singleton or multiple pregnancy, which affects corticosteroid recommendations (e.g., limited evidence for twins).  \\n**Reason**: The guideline notes targeted corticosteroids may be less beneficial in twins. [Reference: Guideline section on \\\"In multiple pregnancies, targeted corticosteroids for early birth should be considered, as there is little evidence of benefit in twins compared to singletons.\\\"]  \\n\\n### Unimportant Recommendations  \\n**Improved patient advice** - The note could explicitly state the betamethasone dose (24 mg) and route (IM) for clarity, though this is likely standard practice.  \\n**Reason**: The guideline specifies the optimum dose/route. [Reference: Guideline section on \\\"The optimum dose and route of administration for a course of antenatal corticosteroids recommend 24mg dexamethasone phosphate or 24 mg betamethasone sodium phosphate/acetate mix given intramuscularly.\\\"]  \\n\\n### Summary of Critical Gaps:  \\n1. **Lack of documented risk-benefit discussion** for late preterm steroids (very important).  \\n2. **Potential delay in delivery** for a non-urgent 6-hour window (somewhat important).  \\n3. **Missing screening for diabetes** (somewhat important).  \\n**Actionable improvements**:  \\n- Add a brief note clarifying the rationale for betamethasone (e.g., \\\"Corticosteroids administered after discussion with patient regarding potential respiratory benefits vs. neonatal hypoglycemia risks\\\").  \\n- Consider earlier delivery if maternal condition deteriorates further.  \\n- Document diabetes screening status.\\n\\n=== GUIDELINE 4: CG11103 Recovery Post Regional and GA Anaesthesia ===\\n### Very Important Recommendations  \\n**Different management plan** - Document a clear post-operative monitoring plan for neurological assessment (including straight-leg raise at 4 hours post-spinal anesthesia) and MEOWS charting frequency (5-minutely for first 15 minutes, then ½ hourly for 1 hour, then hourly until discharge criteria met).  \\n**Reason**: The guideline (CG11103, Section 7.1) mandates straight-leg raise assessment to screen for motor block complications, and Section 7.0 specifies monitoring intervals for regional anesthesia. The note lacks this detail, risking delayed detection of epidural hematoma or residual block.  \\n\\n**Additional information needed** - Include a plan for post-CS urinary output monitoring (hourly for first 2 hours, with escalation if <30mL/hr on two consecutive readings).  \\n**Reason**: Guideline Section 7.0 requires hourly urine output monitoring to detect renal impairment or hypovolemia, critical in preeclampsia.  \\n\\n### Somewhat Important Recommendations  \\n**Improved patient advice** - Explicitly counsel the patient on expected timeline for resolution of spinal anesthesia (3–5 hours) and symptoms requiring urgent reporting (e.g., worsening sensory loss).  \\n**Reason**: Guideline Section 7.1 emphasizes patient education to facilitate early detection of complications like epidural hematoma.  \\n\\n**Additional information needed** - Document pressure area care plan (e.g., repositioning 1–2 hourly, skin assessments) due to immobility post-CS.  \\n**Reason**: Section 10.0 highlights pressure ulcer prevention for anesthetized patients, especially relevant with preeclampsia-associated edema.  \\n\\n### Less Important Recommendations  \\n**Different management plan** - Specify post-CS analgesia/anti-emetics (e.g., paracetamol, NSAIDs if no contraindications) and laxatives in the plan.  \\n**Reason**: Section 11.0 recommends standardized postoperative analgesia, though this is less urgent than hemodynamic monitoring.  \\n\\n**Additional information needed** - Note plans for breastfeeding/infant feeding support post-CS.  \\n**Reason**: Section 11.0 advises extra support for feeding establishment, but this is secondary to maternal stabilization.  \\n\\n### Unimportant Recommendations  \\n**Improved patient advice** - Mention anticipated discharge criteria (e.g., hemodynamic stability, clear fluids tolerance).  \\n**Reason**: Section 9.0 lists discharge criteria, but this is minor compared to acute monitoring needs.  \\n\\n**Note**: The clinical note aligns well with acute management of severe preeclampsia but lacks granularity for post-anesthesia recovery per CG11103. Prioritize adding neurological monitoring, MEOWS documentation, and urinary output tracking.\\n\\n=== GUIDELINE 5: CG13019 Triage of Maternity Patients Guideline ===\\nBased on the provided clinical note and guideline, here are the recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Additional information needed** - Document the time of initial triage assessment and ensure it was completed within 15 minutes of arrival as per BSOTS protocol.  \\n   Reason: The guideline (Section 7.3) mandates that the initial triage assessment should be completed within 15 minutes of arrival to prioritize care effectively.  \\n\\n2. **Different management plan** - Ensure the patient was categorized using the BSOTS algorithm (likely Red or Orange given severe preeclampsia) and document the specific category.  \\n   Reason: The guideline (Section 7.1 and 7.5) requires categorization (Red/Orange/Yellow/Green) to determine the urgency of care and subsequent management steps.  \\n\\n3. **Improved patient advice** - Document detailed counseling on the risks of severe preeclampsia, including potential maternal and fetal complications, and the rationale for urgent delivery.  \\n   Reason: The guideline emphasizes clear communication with the patient (Section 7.7) to ensure understanding of their condition and management plan.  \\n\\n### Somewhat Important Recommendations\\n1. **Additional information needed** - Document whether a MEOWS (Modified Early Obstetric Warning Score) was calculated and reviewed.  \\n   Reason: The guideline (Section 7.3) includes MEOWS as part of the standard assessment for triage.  \\n\\n2. **Different management plan** - Ensure an SBAR (Situation, Background, Assessment, Recommendation) handover was used during transfer to the delivery suite.  \\n   Reason: The guideline (Section 7.6) recommends structured handovers using SBAR for effective communication.  \\n\\n3. **Improved patient advice** - Provide written information on preeclampsia and postpartum monitoring.  \\n   Reason: The guideline (Section 7.7) highlights the importance of patient education and follow-up.  \\n\\n### Less Important Recommendations\\n1. **Additional information needed** - Document whether a translation service was offered if needed.  \\n   Reason: The guideline (Section 7.7) states that translation services should be available for non-English-speaking patients.  \\n\\n2. **Different management plan** - Consider documenting the specific BSOTS algorithm used (e.g., \\\"Hypertension\\\" algorithm).  \\n   Reason: The guideline (Section 7.5) recommends using symptom-specific algorithms for triage.  \\n\\n### Unimportant Recommendations\\n1. **Additional information needed** - Include the midwife’s PIN/stamp on the Triage Assessment Card (TAC).  \\n   Reason: The guideline (Appendix 4) suggests documenting the assessing midwife’s details, though this is minor for clinical care.  \\n\\nThese recommendations ensure the note aligns with the BSOTS triage system and improves compliance with the guideline. Let me know if you'd like further refinements!\\n\\nPlease extract and consolidate actionable suggestions from these multiple guideline analyses. Create combined suggestions when multiple guidelines recommend similar interventions, and prioritize suggestions based on clinical importance and consensus across guidelines. For each suggestion, include detailed context with relevant quoted text from the supporting guidelines.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts multiple clinical guideline analyses into structured, actionable suggestions. You will receive analyses from multiple guidelines and must create a comprehensive set of suggestions that prioritizes the most important recommendations while avoiding redundancy.\\n\\nYour task is to analyze the provided guideline analyses and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nCRITICAL CLINICAL REASONING REQUIREMENTS:\\n- You must first understand the specific clinical scenario and current diagnosis from the transcript\\n- Carefully assess whether each potential recommendation is APPROPRIATE and INDICATED for this specific case\\n- Apply the fundamental principle: \\\"Will this investigation or intervention change management or improve patient care in this specific scenario?\\\"\\n- Consider the clinical context: is this an acute emergency, established diagnosis, or uncertain diagnostic situation?\\n- Distinguish between situations where additional testing is needed vs. where diagnosis is already established\\n- Only recommend interventions that would genuinely improve patient care in THIS specific scenario\\n\\nMULTI-GUIDELINE PROCESSING PRINCIPLES:\\n- Combine and consolidate similar recommendations from different guidelines\\n- Prioritize recommendations that appear in multiple guidelines or are emphasized as critical\\n- Avoid duplicate suggestions - if multiple guidelines suggest the same thing, create one combined suggestion referencing all relevant guidelines\\n- When guidelines conflict, clearly note this and explain the rationale for your recommendation\\n- Organize suggestions by clinical priority and relevance to the case\\n\\nGENERAL CLINICAL APPROPRIATENESS PRINCIPLES:\\n- Do NOT suggest diagnostic investigations when the diagnosis is already established through adequate clinical and/or imaging findings\\n- Do NOT recommend interventions that conflict with the current evidence-based management plan\\n- Do NOT suggest serial monitoring of biomarkers when the clinical picture and imaging provide sufficient diagnostic certainty\\n- Consider whether additional investigations would actually change the management approach\\n- Evaluate the timing: is this the appropriate point in the clinical course for this intervention?\\n- Apply cost-benefit analysis: does the potential benefit justify the intervention in this specific case?\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"combinedSuggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"detailed explanation of why this change is suggested, including relevant quoted text from the guidelines in quotation marks, and confirmation that this recommendation is appropriate for the specific clinical scenario\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"sourceGuidelines\\\": [\\\"Guideline 1 Name\\\", \\\"Guideline 2 Name\\\"],\\n      \\\"consolidatedFrom\\\": \\\"explanation of how this suggestion combines recommendations from multiple guidelines, if applicable\\\"\\n    }\\n  ],\\n  \\\"guidelinesSummary\\\": [\\n    {\\n      \\\"guidelineTitle\\\": \\\"Guideline Name\\\",\\n      \\\"keyRecommendations\\\": \\\"summary of the most important recommendations from this guideline for this case\\\",\\n      \\\"relevanceScore\\\": \\\"high|medium|low\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for consolidation:\\n- If multiple guidelines recommend the same intervention, create ONE suggestion that references all relevant guidelines\\n- Prioritize suggestions that are consistently recommended across multiple guidelines\\n- When guidelines provide different specifics for the same general recommendation, include the most comprehensive/specific version\\n- If guidelines conflict, choose the most appropriate recommendation for this specific case and explain why\\n\\nImportant guidelines for context field:\\n- Provide detailed explanations including WHY the change is needed AND why it's appropriate for this specific case\\n- Include specific quoted text from the relevant guidelines using quotation marks\\n- Reference which specific guidelines support this recommendation\\n- Explain the clinical rationale behind the suggestion\\n- EXPLICITLY state why this recommendation is indicated in this particular clinical scenario\\n- Make the context informative and educational\",\n  \"transcript_length\": 1888,\n  \"guidelines_count\": 5,\n  \"guideline_titles\": [\n    \"CG1198 Management of Hypertensive disorders of pregnancy\",\n    \"MP019 Hypertension and Pre-eclampsia in Pregnancy\",\n    \"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\",\n    \"CG11103 Recovery Post Regional and GA Anaesthesia\",\n    \"CG13019 Triage of Maternity Patients Guideline\"\n  ]\n}\n\nA: {\n  \"combinedSuggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Document whether aspirin prophylaxis was given during pregnancy\",\n      \"suggestedText\": \"Document aspirin prophylaxis status (150mg daily from 12-36 weeks) given family history of pre-eclampsia\",\n      \"context\": \"CG1198 Section 7.0-7.2 recommends aspirin for women with ≥1 high risk or ≥2 moderate risk factors. Family history of pre-eclampsia is a moderate risk factor. This is critical for understanding if preventive measures were implemented and for future pregnancy counseling.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"CG1198 Management of Hypertensive disorders of pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Plan for caesarean section within 6 hours\",\n      \"suggestedText\": \"Re-evaluate delivery timing - consider expediting if maternal condition deteriorates, with vaginal delivery as option if clinically appropriate\",\n      \"context\": \"CG1198 Section 11.1.2 states vaginal delivery should be considered if maternal/fetal condition allows. Antenatal Corticosteroids guideline emphasizes not delaying birth for steroids if health is at risk. Given severe hypertension (MAP 131), hyperreflexia, and HELLP criteria, earlier delivery may be warranted.\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"CG1198 Management of Hypertensive disorders of pregnancy\", \"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\"],\n      \"consolidatedFrom\": \"Combined from two guidelines addressing delivery timing/mode\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"BP consistently elevated at 168/112 mmHg\",\n      \"suggestedText\": \"Calculate and document MAP (currently ~131 mmHg) and specify labetalol dosing regimen/target BP (135/85 mmHg)\",\n      \"context\": \"MP019 Section 9 defines MAP ≥125 mmHg as obstetric emergency. Section 9.4-9.7 details stepwise IV labetalol protocol. Precise BP targets and medication dosing are critical for acute management of severe hypertension in pre-eclampsia.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Urinalysis shows 3+ protein\",\n      \"suggestedText\": \"Obtain protein:creatinine ratio (PCR) to quantify proteinuria (threshold >30mg/mmol)\",\n      \"context\": \"MP019 Section 2.2.3 recommends PCR >30mg/mmol as threshold for significant proteinuria. Dipstick alone is insufficient for definitive diagnosis and baseline documentation. This quantitative measure is important for diagnostic certainty and monitoring.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Magnesium sulfate infusion started for seizure prophylaxis\",\n      \"suggestedText\": \"Document magnesium sulfate monitoring protocol (hourly reflexes/respiratory rate, strict input-output)\",\n      \"context\": \"MP019 Section 8.7 and CG112 (referenced) mandate close monitoring for magnesium toxicity. Given this patient's renal impairment (creatinine rise), precise monitoring is essential to prevent complications while maintaining therapeutic effect.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Risks explained\",\n      \"suggestedText\": \"Document detailed counseling on: 1) Long-term cardiovascular risks 2) Corticosteroid risks/benefits 3) Postnatal follow-up plan\",\n      \"context\": \"MP019 Section 19.1-19.4 mandates counseling on recurrence risks and cardiovascular disease. Antenatal Corticosteroids guideline requires discussion of late preterm steroid risks (hypoglycemia) vs benefits. CG1198 Section 15.0 outlines postnatal follow-up needs. Comprehensive counseling is critical for this high-risk patient.\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\", \"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\", \"CG1198 Management of Hypertensive disorders of pregnancy\"],\n      \"consolidatedFrom\": \"Combined from three guidelines addressing patient counseling needs\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Cross-match for 4 units of blood\",\n      \"suggestedText\": \"Consider CVP line insertion given oliguria (creatinine rise) and HELLP criteria (platelets 98, elevated LFTs)\",\n      \"context\": \"MP019 Section 12.1 recommends CVP for oliguria unresponsive to fluids or HELLP suspicion. This patient meets biochemical HELLP criteria and has renal impairment, making hemodynamic monitoring crucial for fluid management and prevention of pulmonary edema.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"MP019 Hypertension and Pre-eclampsia in Pregnancy\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"Anesthetic consultation arranged\",\n      \"suggestedText\": \"Document post-CS monitoring plan: 1) Neurological assessments (straight-leg raise) 2) MEOWS charting 3) Hourly urine output\",\n      \"context\": \"CG11103 Section 7.0-7.1 mandates specific post-regional anesthesia monitoring. With preeclampsia and potential HELLP, hourly urine output is critical (CG11103 Section 7.0). MEOWS facilitates early detection of deterioration (CG13019 Section 7.3).\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"CG11103 Recovery Post Regional and GA Anaesthesia\", \"CG13019 Triage of Maternity Patients Guideline\"],\n      \"consolidatedFrom\": \"Combined from two guidelines addressing postoperative monitoring\"\n    },\n    {\n      \"id\": \"9\",\n      \"originalText\": \"Betamethasone given for fetal lung maturity\",\n      \"suggestedText\": \"Document rationale for late preterm steroids (36+4 weeks) after risk-benefit discussion\",\n      \"context\": \"Antenatal Corticosteroids guideline states corticosteroids at 35+0 to 36+6 weeks require careful consideration. Documentation should reflect discussion of respiratory benefits vs neonatal hypoglycemia risks, especially with imminent delivery.\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"sourceGuidelines\": [\"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    },\n    {\n      \"id\": \"10\",\n      \"originalText\": \"Partner informed of urgent nature\",\n      \"suggestedText\": \"Document BSOTS triage category (likely Red) and SBAR handover during transfer\",\n      \"context\": \"CG13019 Section 7.1/7.5 requires categorization using BSOTS algorithm. Section 7.6 recommends SBAR for handovers. Severe preeclampsia with end-organ involvement qualifies as Red category, impacting resource allocation and communication.\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"sourceGuidelines\": [\"CG13019 Triage of Maternity Patients Guideline\"],\n      \"consolidatedFrom\": \"Single guideline recommendation\"\n    }\n  ],\n  \"guidelinesSummary\": [\n    {\n      \"guidelineTitle\": \"CG1198 Management of Hypertensive disorders of pregnancy\",\n      \"keyRecommendations\": \"Aspirin prophylaxis for at-risk women, individualized delivery planning, long-term cardiovascular risk counseling\",\n      \"relevanceScore\": \"high\"\n    },\n    {\n      \"guidelineTitle\": \"MP019 Hypertension and Pre-eclampsia in Pregnancy\",\n      \"keyRecommendations\": \"Quantitative proteinuria assessment, CVP for HELLP/oliguria, precise BP targets, magnesium monitoring\",\n      \"relevanceScore\": \"high\"\n    },\n    {\n      \"guidelineTitle\": \"Antenatal Corticosteroids for Improving Neonatal Outcomes in Preterm Birth\",\n      \"keyRecommendations\": \"Risk-benefit discussion for late preterm steroids, avoid delivery delay for corticosteroids\",\n      \"relevanceScore\": \"medium\"\n    },\n    {\n      \"guidelineTitle\": \"CG11103 Recovery Post Regional and GA Anaesthesia\",\n      \"keyRecommendations\": \"Post-CS neurological monitoring, MEOWS, strict urine output tracking\",\n      \"relevanceScore\": \"medium\"\n    },\n    {\n      \"guidelineTitle\": \"CG13019 Triage of Maternity Patients Guideline\",\n      \"keyRecommendations\": \"BSOTS categorization, SBAR handovers, MEOWS documentation\",\n      \"relevanceScore\": \"low\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 4620\nCompletion tokens: 1999\nTotal tokens: 6619\nEstimated cost: $0.003309",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 4620,
    "completion_tokens": 1999,
    "total_tokens": 6619,
    "estimated_cost_usd": 0.0033095
  }
}